目的 探討重組人干擾素α1b注射液聯(lián)合紫杉醇注射液和卡鉑注射液（方案）TP治療卵巢癌的臨床療效。方法 選取2016年1月-2017年1月咸寧市第一人民醫(yī)院收治的卵巢癌患者120例為研究對象，采用隨機數(shù)字法將所有患者分為對照組和治療組，每組各60例。對照組靜脈滴注紫杉醇注射液，135~175 mg/m²加入到生理鹽水500 mL中，間隔1 h靜脈滴注卡鉑注射液，75 mg/m²。治療組在對照組治療的基礎(chǔ)上皮下注射重組干擾素α1b注射液，30~50μg/次，1次/2 d。兩組患者均治療16周后評價療效。觀察兩組的臨床療效，比較兩組的健康狀況調(diào)查簡表（SF-36）評分。結(jié)果 治療后，對照組和治療組的臨床有效率（ORR）分別為30.00%、56.67%，疾病控制率（CBR）分別為66.67%、88.33%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）。治療后，兩組軀體功能評分、認(rèn)知功能評分、社會功能評分、角色功能評分、情緒功能評分均明顯升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組SF-36評分指標(biāo)明顯高于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 重組人干擾素α1b注射液聯(lián)合TP方案治療卵巢癌具有較好的臨床療效，可改善患者生活質(zhì)量，安全性較好，具有一定臨床推廣應(yīng)用價值。

Objective To investigate the effect of Recombinant Human Interferon α1b Injection combined with Paclitaxel Injection and Carboplatin Injection (TP scheme) in treatment of ovarian cancer. Methods Patients (120 cases) with ovarian cancer in the First People's Hospital of Xianning from January 2016 to January 2017 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were iv administered with Paclitaxel Injection, 135-175 mg/m² added into normal saline 500 mL, and after 1 h, patients in the control group were iv administered with Carboplatin Injection, 75 mg/m². Patients in the treatment group were sc administered with Recombinant Human Interferon α1 b Injection on the basis of the control group, 30-50 μg/time, twice daily. Patients in two groups were treated for 16 weeks. After treatment, the clinical efficacies were evaluated, and the SF-36 scores in two groups were compared. Results After treatment, the ORR in the control and treatment groups were 30.00% and 56.67%, respectively, and the CBR in the control and treatment groups were 66.67% and 88.33%, respectively, and there was difference between two groups (P<0.05). After treatment, somatic function scores, cognitive function scores, social function scores, role function scores, and emotional function scores in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And SF-36 scores in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P<0.05). Conclusion Recombinant Human Interferon α1b Injection combined with TP scheme has clinical curative effect in treatment of ovarian cancer, can improve the quality of life of patients, with good safety, which has a certain clinical application value.